Critiquing: In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…

“Orac” / Dr. David H. Gorski posted his lame 6/3/2013 excuse for a review of Burzynski: Cancer Is Serious Business, Part II (2), and I critiqued it:

Critiquing: In which the latest movie about Stanislaw Burzynski “cancer cure” is reviewed…with Insolence:
https://stanislawrajmundburzynski.wordpress.com/2013/07/18/critiquing-in-which-the-latest-movie-about-stanislaw-burzynski-cancer-cure-is-reviewed-with-insolence-2/
7/17/2013 Gorski pushed out his “best” effort:

In which Orac does Stanislaw Burzynski propagandist Eric Merola a favor…
http://scienceblogs.com/insolence/2013/07/17/in-which-orac-does-stanislaw-burzynski-propagandist-eric-merola-a-favor/
After my Epic Sharknado Deconstruction of “Orac’s” “review,” I thought it only fair to continue the feeding frenzy with a Burzynski Texas Tornado

Believe it or not, I’m going to do “Dr.” Gorski (who particularly likes me, to the point of thinking, apparently, that I’m a white research supremacist) a favor

“Dr.” Gorski, as you recall, is a supposed “Doctor,” oncologist, breast cancer specialist, cancer (cough-cough) “researcher” who was responsible for two dubious propaganda reviews about documentary films which Eric Merola made re: Stanislaw Burzynski, the cancer doctor who has used “antineoplastons” to treat cancer without having published any final clinical trial evidence that they do what he claims, since his 1st completed phase II (2) clinical trial in 2009

However, no worries

M. D. Anderson did a clinical trial in 2006 and did NOT publish the final results until 6-7 years later, 2/13/2013

Based on that criteria, Burzynski has until 2016-2017 to publish

Back in 2010, Merola released the first of a dynamic duo of films, the first of which was called Burzynski The Movie: Cancer Is A Serious Business (as Gorski likes to call it, by adding an “A” in the title)

The sequel, the slightly less pretentiously titled Burzynski: Cancer Is A Serious Business, Part 2 (as Gorski again likes to call it with the “A”), was then released June 1 on various pay-per-view modes

As has been pointed out, it’s better than the first, and it features direct attacks on The Skeptics™, or SkeptiCowards©, if you will, who had the temerity to criticize Burzynski and Merola over the last couple of years with their school-yard bully attacks, NOT having the intestinal testicular fortitude to back up their claims with any citation(s), reference(s), and / or link(s) in support of their blatherskite, which they found worthy enough to defend on my blog

Merola is apparently trying to recreate the success of his previous strategy, which involved letting people watch the movie online for free for limited periods of time on websites like Mercola.com

I link directly to the Mercola.com link to the second Burzynski movie, because I want to give Mercola more Google juice than he already has

The movie was, however, on Vimeo until July 20:

BURZYNSKI: CANCER IS SERIOUS BUSINESS, PART II (2013) from BurzynskiMovie on Vimeo
http://articles.mercola.com/sites/articles/archive/2013/07/13/burzynski-cancer-film.aspx
If you want to see what the fuss was about and whether my criticisms of The Skeptics™, or SkeptiCowards©, were valid, now’s your chance

If you want to see the highlighted attack on The Skeptics™ SkeptiCowards©, it begins around 1:19 h into the movie

Yes, I’m encouraging you to watch Burzynski 2

It’s a beautiful example of all the things that Gorski tried to inculcate #TAM2013 attendees against

Indeed, dissecting this magnum opus is an excellent way to teach oneself critical thinking, much as dissecting creationist tripe is

Unfortunately, Gorski is unable to do this, because individuals like me, exist and will NOT let him get away with his disingenuous hack attacks

Other key points include:

Laura Hymas interview and the recording of her discussion with her oncologist (approximately 0:28 h in)

This section is horrifying (to Gorski, at least) to watch, as he can’t help but feel how dicey and ethical the situation that poor UK NHS oncologist found himself in with Hymas and her family demanding that he help her be part of one of Burzynski’s “clinical trials” by agreeing to be the local physician and agreeing to order various scans

The end of the story of Amelia Saunders (approximately 0:58 h in)

This is one where Merola caused Gorski true revulsion, as he basically implied that Amelia died because her parents took her off the antineoplastons

Or you can read what Eric Merola REALLY posted on Twitter:
https://stanislawrajmundburzynski.wordpress.com/2013/04/18/fact-checking-httpthehoustoncancerquack-com/
Hideaki Tsuda’s clinical trial (approximately 1:31 h in)

Gorski wonders why he hasn’t yet published, just like he wonders why Burzynski hasn’t published, but Gorski, SkeptiCoward© that he is, can NOT seem to explain why The Lancet Oncology Peer Review Team D-12-01519 refused to publish Burzynski’s 11/26/2012 (1:29:53) phase 2 clinical trial Progression-Free Survival (PFS) and Overall Survival (OS) re patients 8 – 16 years after diagnosis, results

Those of you who watch it, let Gorski know what you think

Those of you who can only watch part of it, let Gorski know what you think of that section

Remember, though, Gorski will BLOCK you if you question HIS infallibility, because he and his “Oracolytes” would rather comment on things that have NOTHING WHATSOEVER to do with Burzynski, like:

“it is possible to link without boosting google rankings through the “no-follow command”: http://en.wikipedia.org/wiki/Nofollow I learned about this from Bob Blaskiewicz, who proposed that we use this when linking to dubious websites in our posts”

Gorski makes unreliable excuses for NOT doing research re Burzynski, so I did it for him

Burzynski: Complete Response, Partial Response, Stable Disease, Progressive Disease, Objective Response, and Response:
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-complete-response-partial-response-stable-disease-progressive-disease-objective-response-and-response/
Burzynski: Progression-Free Survival (PFS):
https://stanislawrajmundburzynski.wordpress.com/2013/07/04/burzynski-progression-free-survival/
Antineoplastons: Adverse Effects:
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/antineoplastons-adverse-effects/
Burzynski: Acknowledgements, Authors, and Co-Investigators:
https://stanislawrajmundburzynski.wordpress.com/2013/07/03/burzynski-acknowledgements/
Burzynski: Institutional Review Board (IRB):
https://stanislawrajmundburzynski.wordpress.com/2013/07/02/burzynski-institutional-review-board-irb/
And because Gorski and others do NOT seem to understand how antineoplastons (ANP) A10 (Atengenal) and AS2-1 (Astugenal) work, I provide the relevant Burzynski publications and page #’s for them to review:
http://www.burzynskiclinic.com/scientific-publications.html
======================================
Interim Reports on Clinial Trials
16. 2003 (BT-11)
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/960.pdf
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101

Pg. 92
Antineoplaston A10 and AS2-1 are synthetic derivatives of phenylacetate (PN) acid, glutamine and isoglutamine

A10 is sterile solution of sodium phenylacetylisoglutiminate (isoPG) in 4 : 1 ratio

Antineoplaston AS2-1 is sterile solution of sodium phenylacetate (PN) and phenylacetylglutaminate (PG) in 4 : 1 ratio

Pg. 97
Discussion
Pg. 99

======================================
Review Articles on Clinical Trials:
1. 3/2004
The Present State of Antineoplaston Research
http://www.burzynskiclinic.com/images/stories/Publications/994.pdf
Integrative Cancer Therapies 2004;3:47-58
Volume 3, No. 1, March 2004
DOI: 10.1177/1534735-403261964
Volume 3 Number 1 March 2004

Pg. 47
Pg. 48
Mechanism of Action of Antineoplaston
Pg. 49
Pg. 50

The reason for 50% Progressive Disease (PD) in studies is long dose-escalation process, which extends to more than a month’s time period, before the optimal dosage is reached

Pg. 56
Conclusion

======================================
Case Reports:
4. 9/2004 (Special Exception (SE) to BT-11 Study (ST))
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1145.pdf
Integrative Cancer Therapies 2004;3:257-261
Volume 3, Number 3 September 2004
DOI: 10.1177/1534735404267748

Pgs. 257-258
Pg. 260
Discussion
Pg. 261

======================================
Interim Reports on Clinial Trials:
2. 10/2004
Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme
http://www.burzynskiclinic.com/images/stories/Publications/1218.pdf
Neuro-Oncology. 2004; 6: 384
Volume 6 Issue 4 October 2004
Abstracts from the Society for Neuro-Oncology Ninth Annual Meeting, Toronto, Ontario, Canada, November 18-21, 2004

Pg. 385
======================================
Interim Reports on Clinial Trials:
3. 10/2004 (Study (ST) and Special Exception (SE))
Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma
http://www.burzynskiclinic.com/images/stories/Publications/1219.pdf
Neuro-Oncology. 2004; 6: 386
Volume 6 Issue 4 October 2004

Antineoplastons (ANP) consist of 3 active ingredients including sodium salts of phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetic acid (PN)

Preclinical data supports that the mechanism of antineoplastic activity in DBSG, involves interruption of signal transmission in the RAS, (PN) AKT2, and TGFB1 (PG) pathways, activation of p53 and p21 tumor suppressor genes (PN) and apoptosis (PG and isoPG)

======================================
Interim Reports on Clinial Trials:
17. 2004 (BT-13 and BT-23)
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma :
a preliminary report
DRUGS IN R&D
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs in R and D
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
(Drugs in Research and Development)
http://www.burzynskiclinic.com/images/stories/Publications/1194.pdf
Drugs R D. 2004;5(6):315-26
Drugs R&D 2004;5(6):315-326.

Pg. 316
Pg. 324
Discussion

======================================
Interim Reports on Clinial Trials:
18. 6/2005 (CAN-01 and BT-12)
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integrative Cancer Therapies 2005;4(2):168-177
http://www.burzynskiclinic.com/images/stories/Publications/1220.pdf
DOI: 10.1177/1534735405276835
http://m.ict.sagepub.com/content/4/2/168.long?view=long&pmid=15911929
Volume 4 Number 2 June 2005

Pg. 168
Pg. 174
Discussion
Pgs. 175-176

======================================
Interim Reports on Clinial Trials:
19. 3/2006 (BT-03, BT-11, BT-18, and CAN-01)
Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma.
http://www.ncbi.nlm.nih.gov/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integrative Cancer Therapies 2006;5(1):40-47
http://www.burzynskiclinic.com/images/stories/Publications/5825.pdf
DOI: 10.1177/1534735405285380
http://m.ict.sagepub.com/content/5/1/40.long?view=long&pmid=16484713

Pgs. 40-41
Pg. 46
Discussion
Conclusion

======================================
Interim Reports on Clinial Trials:
8. 10/2006
Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1.
http://www.burzynskiclinic.com/images/stories/Publications/2105.pdf
Neuro-Oncology. 2006; 8:466.
Volume 8 Issue 4 October 2006
Abstracts for the Eleventh Annual Meeting of the Society for Neuro-Oncology (SNO)

Pg. 466
Antineoplastons (ANP) are synthetic analogues of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

======================================
Review Articles on Clinical Trials:
3. 12/2007
Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007; 5, 379-390.
http://www.burzynskiclinic.com/images/stories/Publications/5692.pdf
Review Article
Cancer Therapy Vol 5, 379-390, 2007
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
Volume 5 Number 2 December, 2007

Pg. 381
Pg. 384
E. Multitargeted therapy

======================================
Interim Reports on Clinical Trials:
11. 10/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma:
A preliminary report
http://www.burzynskiclinic.com/images/stories/Publications/7853.pdf
Volume 10 Issue 5 October 2008
Neuro-Oncology 2008; 10:821
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology, November 20-23, 2008

Pg. 821

Antineoplastons (ANP) are synthetic analogs of naturally occurring phenylacetylglutamine (PG), phenylacetylisoglutimine (isoPG), and phenylacetate (PN)

Antineoplastons (ANP) is a multi-targeted therapy affecting signal transduction, the cell cycle, the TCA cycle, and apoptosis

======================================
Interim Reports on Clinical Trials:
12. 12/2008
(BT-8 – PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
(BT-15 – ADULT PATIENTS WITH ANAPLASTIC ASTROCYTOMA)
Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma
http://www.burzynskiclinic.com/images/stories/Publications/7898.pdf
Neuro-Oncology 2008; 10:1067
Volume 10 Issue 6 December 2008
Abstracts for the Eighth Congress of the European Association for Neuro-Oncology (EANO), Sept. 12-14, 2008, Barcelona, Spain

Antineoplastons (ANP) affects multiple targets, and its components have different mechanisms of action

A10 interferes with signaling in the AKT2 and MYCC pathways, blocks expression of TGFB1, activates the PTEN and MAD tumor suppressor genes, and normalizes nuclear transport by decreasing the expression of RANBP1, which may restore the activity of the mutated INI protein

AS2-1 interferes with signal transmission in the RAS and BCL2 pathways and activates expression of the tumor suppressors TP53 and p21

======================================
Case Reports:
1. 12/2009 (BT-11 Special Exception (SE))
Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP).
http://www.burzynskiclinic.com/images/stories/Publications/8638.pdf
Neuro-Oncology 2009; 11:923.
Volume 11 Issue 6 December 2009
Abstracts from the Third Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) and the Sixth Meeting of the Asian Society for Neuro-Oncology (ASNO), May 11-14, 2009, Yokohama, Japan

Antineoplastons (ANP) is a multi-targeted therapy that is well tolerated with minimal and reversible adverse events and has multiple different mechanisms of action by affecting the AKT, RAS, TP53, p21, and PTEN pathways
======================================

Advertisements

David H. Gorski’s conspiracy-mongering and more of his Dr. Stanislaw Burzynski “stories”

Eric Merola’s conspiracy-mongering and more of Dr. Stanislaw Burzynski’s cancer “success” stories

David Gorski (@gorskon) tweeted at 5:23am – 15 Apr 13:
http://t.co/8Fb4GD7hkK’s-cancer-“success”-stories-part-2

Bob Blaskiewicz (@rjblaskiewicz) tweeted at 5:52am – 15 Apr 13:

ScienceBasedMed (@ScienceBasedMed) tweeted at 12:28pm – 15 Apr 13:
http://t.co/5MNwcmHEPW

ScienceBasedMed (@ScienceBasedMed) tweeted at5:35pm – 15 Apr 13:
http://t.co/5MNwcmHEPW

Because promoting it once just isn’t good enough

4/15/2013 David H. Gorski tweeted away about his blog, about Eric Merola’s second movie, about Stanislaw Burzynski, Burzynski: Cancer Is A Serious Business, Part 2

A ?

Or, as they might say in Toronto, Canada,

Aye ?

Maybe this is the “screening” title, as opposed to:

“Burzynski: Cancer Is Serious Business, Part II”

@Gorskon mentions the “Skeptic Mule,” Brian Thompson, from the James Randi Educational Foundation (jref)
http://www.randi.org/site/index.php/swift-blog/2050-qburzynski-iiq-is-more-of-the-same.html
@OracKnows implies that he took advantage of his supposedly “awesome” commentary about his experience on the JREF Swift Blog,
https://stanislawrajmundburzynski.wordpress.com/2013/04/02/finally-james-randi-educational-fund-jref-wins-an-award-that-they-richly-deserve
and his “alleged” “COPIOUS notes,” which I referred to in my blog:
https://stanislawrajmundburzynski.wordpress.com/2013/03/14/my-1st-hand-review-of-oracs-2nd-hand-review-burzynski-cancer-is-serious-business-part-ii
Gorski dishonestly demonizes what he refers to as “them” (i.e., Eric Merola) and mentions the skeptics promoted in Burzynski II, all with a heapin’ helpin’ of conspiracy-mongering

In this post, I will delve into a little more detail about the fundamental intellectual dishonesty behind Orac’s conspiracy-mongering

In particular, note how everything I said in my previous posts about what went on at the Q&A is verified, and, in fact, you now have the details

I will try to mention the specific time points to refer to as I go along

Also note that there is a segment at about the 47:45 mark in which JREF’s Brian Thompson (blurred out but still recognizable) speaks with the husband of one of Burzynski’s patients that is worth watching and that I will briefly discuss further into this post

3 things

3 things got me to thinking that I was probably due to write about Stanislaw Burzynski and his “Conspiracy Theory” propagandist Gorski again

The 1st thing, of course, was Gorski’s blog

The 2nd thing was the Q&A video

The 3rd thing was a rather odd online encounter that I had with @gorskon a couple of days ago

It was so bizarre that it left me scratching my head and thinking that @gorskon really needs to look at how he appears online

Either that, or he’s losing it

Regular readers probably remember that a couple of weeks ago I posted a shameless self-plug featuring a link to a YouTube video of a talk he did for the National Capital Area Skeptics on March 9 (which I can’t resist embedding my 21 point skidoo review blog again, for those of you who might not have seen it—forgive me):

Critiquing David H. Gorski – Quackademic Medicine
https://stanislawrajmundburzynski.wordpress.com/2013/04/02/critiquing-david-h-gorski-quackademic-medicine
apparently Merola saw the video too

It didn’t take long at all for @gorskon to get himself hence to Twitter to start tweeting:

David Gorski (@gorskon) tweeted at 10:08pm – 12 Apr 13:

David Gorski (@gorskon) tweeted at 7:34pm – 13 Apr 13:

which made me want to be sure to immortalize it

I’m not sure if it was embarrassment or a stab of conscience, but Gorski’s immortal comments where he mentions that Eric Merola had contacted him about appearing in Burzynski: Cancer Is Serious Business, Part 2, is now gone from his blog, or hiding from me:

Didymus Judas Thomas

#52 – Didymus Judas Thomas

At the Tu-Quack Center ScienceBasedMedicine Room

January 15, 2013

Don’t worry Orac, no one is going to mistake you for Vincent Kennedy McMahon; HE actually has a Gigantic Pair of Grapefruits! I find it amazing that you can communicate with EM about getting to say what you want to say, but then amazingly can’t communicate about not wanting any videos, music, pictures, or whatever else “Conspiracy Theory” misgivings you fear. It’s not about “Carpe Diem” for you, it’s about “Carpe Don’t!!” That’s just a “Piss-Poor” excuse!!!
http://scienceblogs.com/insolence/2013/01/14/the-story-of-sean-olaighin-patient-of-dr-stanislaw-burzynski
Gorski asks:

“On the other hand, what’s worse than being a white supremacist?”

Rubbishing the work of multiple M.D.’s and an oncologist ?

Posting

“Misinformation” ?

“Disinformation” ??

(Mis•Dis•Information)

“Misdirection” ???

@ScienceBasedMed
“Apparently I’m also a puppy eater”

David Gorski (@gorskon) tweeted at 12:07pm – 6 Apr 13:
http://t.co/CUJkMpw6jP

Maybe he meant you throw

“puppy Heaters” ?

David Gorski (@gorskon) tweeted at 2:29pm – 30 Mar 13:

David Gorski (@gorskon) tweeted at 2:33pm – 30 Mar 13:

David Gorski (@gorskon) tweeted at 8:35am – 31 Mar 13:

Such is life

However, @gorskon’s ill-considered Twitter adventures got me interested in what he might be up to again, as did learning that he blogged about a Q&A after a screening of Burzynski II in Toronto

Gorski blogged:

“As with Merola’s screening at San Luis Obispo on March 10, this screening in Toronto, which occurred on April 5, was attended by at least one skeptic, who was kind enough to do the same thing our colleagues did in California and provide me with notes”

I wonder if they were “COPIOUS notes” like he “allegedly” received previously?

I hope that my discussion of these blog comments, and Q&A’s and of these twits will serve, along with my previous discussions, as educational background for those who attend further screenings of the Burzynski movie, for example the upcoming screening on April 27 at the Newport Beach Film Festival

Davey doubles down on the conspiracy-mongering

“The very first thing I noticed upon viewing the YouTube video of the Q&A from March was that the sheer conspiracy mongering that Merola engages in was not adequately captured by the notes”

Those “alleged” “COPIOUS notes”?

THAT is truly, truly over the top

Gorski continues:

“For instance, take a look at the segment beginning at about the 13:56 mark, in which Merola discusses how former senior advisor to President Obama David Axelrod allegedly watched the film”

“Merola repeated this very same story near the very beginning of his Q&A in Toronto, although he apparently did preface it with a disclaimer to the effect of something like, “I have no proof of this”

“You can believe me or not.”

“Clearly, the David Axelrod story is going to be a regular feature of Merola’s movie publicity tour, and Merola plans on using it at every Q&A”

“I can only hope that my reporting on it last time led him to add that little disclaimer”

David Gorski (@gorskon) tweeted at 12:27pm – 30 Mar 13:

This is not a mistake

Another “delusion of grandeur”?

Gorski proceeds:

“More importantly, I would love to see whether David Axelrod will actually respond to this, particularly now that we have evidence that Merola is telling this story other than reports of promoters of science-based medicine who were brave enough to go into the veritable lions’ den a month ago”

“Brave enough” ?

“Lions’ Den” ??

really ? Seriously ?? REALLY ???

So, as opposed to you (NOT) appearing in Burzynski 2?

Gorski questions:

“Can you imagine how some of them would react to a pharmaceutical company advertising off-label uses for its drugs?”

Oh, wait

We don’t have to imagine it

We already know

It would be like Orac commenting on a pharmaceutical company being fined $3 BILLION?

Gorski blathers on

“Next up, if you don’t believe me when I told you last time just how much Merola despises anyone whom he considers to be a member of “The Skeptics,” just mosey on over to the segments at the 21:25 and 35:45 marks”

“At the 21:25 mark, Merola is asked, “How did you discover the skeptics’ group and how did you gain access to the videoconference and do you know anything else about them?””

Merola’s answer:

“Sure”

“Basically, these guys have no shame whatsoever”

“They have no problem letting everybody know their names and putting themselves out there”

“I really believe that the lower tier guys, like the guys that you saw, they put that on YouTube and were very proud of it”

“I went through a lawyer to get legal clearance to make sure I was safe”

“That’s why they’re blurred out and their names are hidden”

Gorski blogospheresplats:

“If you want to know the utter intellectual dishonesty of this answer, realize that the segment that Merola included in his movie of “skeptics plotting” was nothing more than a clip taken from the Virtual Skeptics podcast (episode 13, to be precise) in which Bob Blaskiewicz was talking about Burzynski and his plans to raise money for St. Jude’s for Burzynski’s 70th birthday in January”

What David fails to do is describe this birthday “present” in detail as I did on my blog:
https://stanislawrajmundburzynski.wordpress.com/2013/03/26/critiquing-bob-blaskiewicz-burzynski-cancer-is-serious-business-part-ii
Gorski blatherskites on:

“Also note the disconnect between the movie, which, according to reports, implies that skeptics—excuse me, “The Skeptics,” to use Merola’s term in his movie—are some shadowy cabal, while in the Q&A he admits that this stuff is on YouTube”

As if Bobby (Blatherskitewicz) Blaskiewicz’s and pals’ YouTube videos and blog which Merola specifically described as:

” … the LOWER TIER guys, like the guys that you saw, they put that on YouTube … ”

are the relevant part of the so-called

“shadowy cabal”

But none of that matters anyway because, apparently:

Skeptics are calling me an actress or an actor

Sheila Herron (@Ac2cSheila) tweeted at 1:54pm – 31 Mar 12:

Skeptics are saying I’m laundering money

Peter Bowditch (@RatbagsDotCom) tweeted at 8:09pm – 19 Feb 13:

What is going on?”

Gorski posits:

“I wonder if I’m one of the “guys at the top.””

“If I am, this is the first I’ve heard of it”

Don’t worry Davey

It’s a long way to the top if ya wanna Rock and Roll

and, you haven’t even made it to the chorus line

In other words, you’re not even

off, Off, OFf, OFF Broadway yet

“The Skeptics” (Burzynski: Cancer is Serious Business, Part II)
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/the-skeptics
Gorski blathersplats on:

“He goes on to complain about how skeptics have “completely hijacked” Burzynski’s Wikipedia page and how he really really wanted to “call them out,” but for “legal reasons” and “running time.””

Is THAT all you’ve got ?

THIS is just the tip of the bucket list:

“The Skeptics:” Your problem is, Wikipedia IS censored
https://stanislawrajmundburzynski.wordpress.com/2013/04/14/the-skeptics-your-problem-is-wikipedia-is-censored
But Gorski knows this, because when he blocked my comments on his blog, suddenly 2 “alleged” “gatekeepers” got “brave”

#174 – SW – 2/12/2013

[…]
anti-Burzynski “bloggers”
[…]

These individuals are also responsible for “gate keeping” the Wikipedia Page on The Burzynski Clinic

This issue, as well as the identities of those involved, will be covered in great length in the new 2013 “Chapter 2″ documentary

[…]
You will notice the “anti-Burzynski bloggers” refuse to do that or adhere to reputable sources
[…]

As one of those “gate keeping” wikipedians I find this quite laughable – not only the threat of “covering” my identity, but also the suggestion that bloggers and wikipedians (there may be an overlap, but I can assure you that I’m not a blogger) refuse to check and adhere to reputable sources

#203 – novalox – 2/13/2013

Now, let’s just wait and see djt make accusations of persecution and unfairness

Should be entertaining to see his attempts at this

Oh, BTW, djt, if you are still reading this, I was one of the Wikipedia editors who reported you for your trolling behaviors there

Have fun with that
http://scienceblogs.com/insolence/2013/02/08/will-the-fda-finally-slap-down-stanislaw-burzynski-for-good
Gorski splats:

“About 18 months ago, Burzynski made the huge mistake of siccing his attack Teacup Chihuaha Marc Stephens on a teen skeptic in the U.K. by the name of Rhys Morgan”

🙂

Oh !

The infamous “teen skeptic,” @rhysmorgan ?

TheSkeptiCritic (@TheSkeptiCritic) tweeted at 8:12pm – 16 Apr 13:
https://twitter.com/TheSkeptiCritic/status/324329482712391680

http://rhysmorgan.co/blog

http://rhysmorgan.co/burzynski-morally-reprehensible

http://thewelshboyo.wordpress.com
So, where’s your “FACTS” that “PROVE” that Burzynski “sicced” anyone on him?

Don’t have any as usual ?

Gorski rants on:

“When someone like Merola promises to slime me in a movie that will see international distribution, I take notice”

You mean you knew from the beginning that it would have “international distribution”?

Gorski racks up more frequent “conspiracy-mongering” flyer miles

“Around the 35:45 mark, Merola is asked who is paying “The Skeptics” and whether it’s been investigated”

Merola’s response:

“Yeah, I’ve done a lot of that myself, but frankly as you can imagine for legal reasons I just didn’t want to call them out”

“I’m not going to call them out”

“Not yet”

“I know who most all of them are”

“I know what they’re doing”

“But for legal reasons, because these guys are vicious and do not care about the truth—they only care about winning—and I don’t want to give them any reason to damage me any further or at all, frankly”

“So, yes, it’s been done, but they’re slippery, slippery people, and I’m not going to go any farther than that”

“But that would be a great thing, to have someone do a separate investigative report on just these guys, because most people—the festival staff, most people that watched it—said, “I’ve never even heard of these guys”

“I didn’t even know they existed.””

“Then they go back online, and they realize, wow, so they’re the ones doing all the damage online”

“They’re the ones doing this and that”

“That’s the best I can answer that”

“I’ve been trying to be careful myself, because they’re really nasty people”

Gorski theorizes:

“I was struck by how paranoid this sounded, even more so than I had expected based on reports I received”

Too bad you weren’t able to eruditely explain in detail how it’s supposedly “paranoid”

Gorski rambles:

“I was also further struck at how Merola describes Burzynski critics, who according to him are more than happy—proud, even—to “put their names out there” as “spineless,” when he himself has decided for legal reasons not to “name names.””

What would you like better ?

Liars ?

Cowards ??

Dissimulators ???

Gorski rattles off:

“One can’t help but wonder if maybe—just maybe—the reason Merola’s lawyers told him not to “name names” is because they realized that much of what he says is likely to be libelous”

Would you like me to do some of it for him?

Gorski ruminates:

“Certainly, I consider it so from what I’ve been able to gather”

But then again, you don’t believe in “Free Speech” on your blog

Stanislaw Rajmund Burzynski, M.D., Ph.D and “Freedom of Speech”
https://stanislawrajmundburzynski.wordpress.com/2013/03/24/stanislaw-rajmund-burzynski-m-d-ph-d-and-freedom-of-speech

Gorski insists:

“In any case, what really bothers Merola is he knows damned well that I’ve actually read nearly every paper I can get my hands on about antineoplastons”

“I also have the skill set to analyze them, and I wasn’t impressed”

Like I have NOT been impressed by your lack of “fact-checking” and NOT backing up what you twit and blog about?

Gorski postulates:

” … their willingness becomes particularly problematic in the case of Tori Moreno”

“Moreno is a Burzynski patient from the late 1990s who is now 14 years old”

“She appeared in the video above and is scheduled to appear again with Eric Merola at the Newport Beach Film Festival screening, along with her parents”

“She was clearly nervous on stage, and it was clearly her father who was driving the bus, so to speak”

“I must admit that I have a real problem with her being used this way”

And in reference to adults he comments:

” … they are considered competent to make their own decisions with respect to speaking out”

“Such is not the case with an underage teen like Tori Moreno”

“From my point of view, poor Tori is being used as nothing more than a prop by Eric Merola and, sadly, her father to be presented as “living proof” that Burzynski’s therapy works”

So, Gorski “thinks” (?) Tori is NOT “competent” to make her “own decisions with respect to speaking out”

But is she?

(“Such is not the case with an underage teen like Tori Moreno”)

Well, NOT if you’re “Dr. Free Speech”

And that’s something that needs to be said publicly

Gorski thinks we’re supposed to be impressed by:

“According to the NCI, treatment options include:”

“Therapeutic options include watchful waiting; …”

which refers to patents with dates from 2004 and 2005 re a Burzynski patient being treated about 10 years before those patents, in 1995

So what to make of all this?

Lessons for those who would oppose “The Skeptics”

Gorski’s comments re:

The Q&A session at San Luis Obispo and what I’ve learned about the Q&A session after the Toronto screening of Burzynski II provide many lessons for unbiased individuals and critics of skeptics who don’t “fact-check”

First and foremost, to me, at least, is the lesson that David H. Gorski can’t be trusted

He is a true believer, and he despises fact-checking

For instance, he clearly plans on repeating that Eric Merola clearly plans on repeating an “unbelievable” story about David Axelrod, even though there is NO indication that David’s done due diligence

Like below where he states:

“He demonstrates time and time again that he does not understand science, clinical trials, or why science-based oncologists do not take Burzynski seriously”

I guess the people that work at these places do NOT “take Burzynski seriously” either:

3/2011 – PHASE II TRIAL of tipifarnib and radiation in CHILDREN with newly diagnosed diffuse intrinsic pontine GLIOMAS
http://www.ncbi.nlm.nih.gov/m/pubmed/21339191
University of California—San Francisco

Children’s Hospital Boston, Massachusetts

St Jude Children’s Research Hospital, Memphis, Tennessee

Seattle Children’s Hospital, Seattle, Washington

Children’s Hospital of Philadelphia, Pennsylvania

Children’s Hospital of Pittsburgh, Pennsylvania

Children’s National Medical Center, Washington, DC

Cincinnati Children’s Hospital Medical Center, Ohio

Neuro Oncol (2011) 13 (3): 298-306
doi: 10.1093/neuonc/noq202

http://neuro-oncology.oxfordjournals.org/content/13/3/298.full
Neuro Oncol (2011) 13 (3): 298-306. doi: 10.1093/neuonc/noq202
5.723 Impact Factor

REFERENCE:

25. ↵ BURZYNSKI SR

Treatments for astrocytic TUMORS in CHILDREN: current and emerging strategies

Paediatr Drugs. 2006;8:167-178
http://link.springer.com/article/10.2165%2F00148581-200608030-00003
Pediatric Drugs
May 2006, Volume 8, Issue 3, pp 167-178

He’s using every tool at his disposal and is willing to cherry pick and distort information, and in general demonstrate no regard for the truth

In other words, one thing that anyone who wants to criticize Gorski should know is that Gorski is not convincible, not trustworthy, and likely to use whatever internet sources he has to attack, and anyone who wants to confront Gorski at a Q&A with a critical question needs to be prepared for the types of spin he will bring to bear

In particular, that includes not giving him what I like to call a “weasel” opening that allows him to attack based on one mistake and ignore everything else

He’s very good at that

Gorski ejaculates:

“The problem is the quality (more specifically, the lack thereof) and utterly unconvincing nature of Burzynski’s publications”

“He publishes in bottom-feeding journals and has not yet published a completed phase II clinical trial”

“That’s plenty bad enough”

“Burzynski has only published abstracts and partial reports on phase II trials, none of which are particularly convincing”

“His publications are all, as far as I’ve been able to tell, crap, and I’ve read nearly all of them”

This leaves one to wonder why DHG does NOT cite any US Department of Health and Human Services (HHS), Food and Drug Administration (FDA), or National Cancer Institute (NCI) at the National Institutes of Health (NIH) document that supports his position as to the RELEVANCE of the Impact Factor of any journal Burzynski has or may publish in, nor does he back up his comments re the Preliminary Reports that Burzynski has published re the Phase II clinical trials:

Drugs in R & D (Drugs in Research and Development)

2003 – Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101

6 months median duration of treatment

of all 12 patients
2 years / 33.3% – Survival
2 / 17% – alive and tumour free for over 5 years since initial diagnosis

from start of treatment
5 years – 1 alive for more than
4 years – 1 alive for more than

Only mild and moderate toxicities were observed, which included

3 cases of skin allergy

2 cases of:
anaemia
fever
hypernatraemuia

single cases of:
agranulocytosis
hypoglycaemia
numbness
tiredness
myalgia
vomiting

2003 – Protocol – recurrent diffuse intrinsic brain stem glioma
12 – Patients Accrued
10 – Evaluable Patients
2 / 20% – # and % of Patients Showing Complete Response
3 / 30% – # and % of Patients Showing Partial Response
3 / 30% – # and % of Patients Showing Stable Disease
2 / 20% – # and % of Patients Showing Progressive Disease

2004 – Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26

incurable recurrent and progressive multicentric glioma

antineoplaston A10 and AS2-1 (ANP)

9 – patients’ median age

6 patients were diagnosed with pilocytic astrocytoma

4 with low-grade astrocytoma
1 with astrocytoma grade 2

1 case of visual pathway glioma, a biopsy was not performed due to a dangerous location

16 months – The average duration of intravenous ANP therapy

19 months – The average duration of oral ANP

1 patient was non-evaluable due to only 4 weeks of ANP and lack of follow-up scans

1 patient who had stable disease discontinued ANP against medical advice and died 4.5 years later

10 patients are alive and well from 2 to >14 years post-diagnosis

Only 1 case of serious toxicity of reversible tinnitus, of 1 day’s duration, was described

2004 – Protocol – incurable recurrent and progressive multicentric glioma
12 – Patients Accrued
33% – % of Patients Showing Complete Response
25% – % of Patients Showing Partial Response
33% – % of Patients Showing Stable Disease
0 / 0% – # and % of Patients Showing Progressive Disease

Integrative Cancer Therapies

6/2005 – Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77

13 children with recurrent disease or high risk

6 (46%) survived more than 5 years

2005 – Protocol – recurrent disease or high risk
23% – % of Patients Showing Complete Response
8% – % of Patients Showing Partial Response
31% – % of Patients Showing Stable Disease
38% – % of Patients Showing Progressive Disease

3/2006 – Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma
http://www.ncbi.nlm.nih.gov/m/pubmed/16484713
Integr Cancer Ther. 2006 Mar;5(1):40-7

Brainstem glioma carries the worst prognosis of all malignancies of the brain

Most patients with brainstem glioma fail standard radiation therapy and chemotherapy and do not survive longer than 2 years

Treatment is even more challenging when an inoperable tumor is of high-grade pathology (HBSG)

patients with inoperable tumor of high-grade pathology (HBSG) treated with antineoplastons in 4 phase 2 trials

39% – overall survival at 2 years
22% – overall survival at 5 years

17+ years maximum survival for a patient with anaplastic astrocytoma

5+ years for a patient with glioblastoma

39% – Progression-free survival at 6 months

5+ year survival in recurrent diffuse intrinsic glioblastomas and anaplastic astrocytomas of the brainstem in a small group of patients

18 – evaluable
4 – glioblastomas
14 – anaplastic HBSG

14 – diffuse intrinsic tumors
12 – recurrence
6 – did not have radiation therapy or chemotherapy

Antineoplastons, A10 (A10I) and AS2-1 injections

5 months median duration

Responses were assessed by gadolinium-enhanced magnetic resonance imaging and positron emission tomography

Antineoplastons tolerated very well
1 case of grade 4 toxicity (reversible anemia)

2006 – Protocol – high-grade pathology (HBSG)
18 – Evaluable Patients
11% – % of Patients Showing Complete Response
11% – % of Patients Showing Partial Response
39% – % of Patients Showing Stable Disease
39% – % of Patients Showing Progressive Disease

2007 – Recent clinical trials in diffuse intrinsic brainstem glioma

Review Article
http://www.cancer-therapy.org/CT/v5/B/HTML/42._Burzynski,_379-390.html
E. Multitargeted therapy

Antineoplaston A10 injections (A10) consist of synthetic phenylacetylglutaminate sodium (PG) and phenylacetylisoglutaminate sodium (isoPG) in a ratio 4:1

antineoplaston AS2-1 (AS2-1) consists of PG and phenylacetate sodium (PN) in a ratio of 1:4

Phase II studies with ANP included patients with DBSG began 1988
(Burzynski, 2004a)

Only small # of patients with DBSG involved in most studies, which dealt with broad spectrum of primary brain tumors
(Burzynski, 2004a)

1996, phase II study of ANP in patients with brainstem gliomas opened and nearing completion
(Burzynski et al, 2003, 2004a, 2007)

studies are conducted at Burzynski Clinic and monitored by FDA and Institutional Review Board (IRB)

most recent report describes results in children with newly diagnosed DBSG
(Burzynski et al, 2007)

20 evaluable patients
5 with high-grade gliomas

overall survival (OS)
2 years – 40%
5 years – 30%

CR – 30%
PR – 10%
SD – 20%
PD – 40%
(Burzynski et al, 2007)

study closed for accrual and final results will be evaluated before end of 2007

Phase III protocol currently under FDA’s review

Results summarized in Table 2

proposed antineoplastic activity of ANP in DBSG consists of targeted therapy affecting AKT2 and TGFB1 pathways (PG), RAS, TP53, and p21 (PN) MYCC (PG and PN), MAD (PG), INI1 (PG), and apoptosis (PG and isoPG)

PG is formed in patient’s liver from PN and PB, but doesn’t share with PN and PB an inhibitory affect on HDAC

details of these mechanisms have been described previously

(Castillo et al, 1991; Liau et al, 1992; Adam et al, 1995; Liu and Samid, 1995; Shack et al, 1995; Danesi et al, 1996; Gorospe et al, 1996; Prasanna et al, 1996; Adam et al, 1997; Engelhard et al, 1997; Harrison et al, 1998; Ng et al, 2000; Witzig et al, 2000; Li et al, 2001; Burzynski et al, 2003, 2004a,b, 2005; Waldbillig and Burzynski, 2003; Burzynski, 2004b, 2006a,b)

DBSGs remain some of most tragic diagnoses in oncology

general opinion of neuro-oncologists that results of treatment for DBSG constitute worst response in all primary brain tumors

DBSGs occur usually in children, in whom brain tumors in general are 2nd most frequent malignancy, and most common form of solid tumors

Due to poor response, # of clinical trials in DBSG is small, and there isn’t much interest in bringing new agents into approval process by pharmaceutical companies

Results of treatment with antineoplastons A10 and AS2-1 (ANP) in patients with diffuse, intrinsic brain stem glioma

Author – Burzynski et al, 2007
Phase II – Study Type
N – newly diagnosed tumor – Tumor Type
20 – # of patients
ANP – Treatment
ANP – antineoplastons A10 and AS2-1
Efficacy
overall survival
2 yrs / 5 yrs
40% / 30%
median survival time
16.4 – months

6 / 30% – # and % of Patients Showing Complete Response
2 / 10% – # and % of Patients Showing Partial Response
4 / 20% – # and % of Patients Showing Stable Disease
8 / 40% – # and % of Patients Showing Progressive Disease

Most results of phase II trials with targeted therapy and ANP have been presented at oncology meetings and published as abstracts

It was decided to include data from meeting abstracts in order to present most up to date results, but they should be treated with caution until they pass scrutiny of peer review

Children, older than 3 years, and young adults with newly diagnosed tumors, are usually temporarily helped with standard radiation therapy, but it’s estimated that less than 10% of them will survive 2 years

Children, younger than 3 years, adults after age 40, and patients with high-grade glioma pathology have very grave prognosis, and median survival is similar to supratentorial GBM, or worse

Children diagnosed with DBSG and neurofibromatosis 1 have better prognosis, except those that show contrast-enhancement on MRI

prognosis is especially grave for patients with recurrent DBSG, who typically don’t survive longer than 6 months

Targeted radiotherapy and bevacizumab in combination with irinotecan may offer hope, but they would require further clinical trials

The patients with recurrent DBSG can be helped with treatments currently in phase II clinical trials

The results of phase II trials in DBSG with ANP compare favorably with responses and survival data in radiation therapy and chemotherapy trials

Currently conducted phase II studies are closed for accrual and nearing completion, and phase III studies are scheduled to open soon

Introduction of new multitargeted agents and acceleration of basic and clinical research in DBSG may offer better chances in the future

Ouch

I cringed
http://www.sciencebasedmedicine.org/index.php/dr-stanislaw-burzynskis-cancer-success-stories-part-2/#more-25645
Hopefully I didn’t fail to convey the full scope of “The Skeptics” true conspiracy theory awesomeness

That was awesome